The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
The economic burden of visual impairment and blindness: a systematic review
Open accessAbstract
Objectives: Visual impairment and blindness (VI&B) cause a considerable and increasing economic burden in all high-income countries due to population ageing. Thus, we conducted a review of the literature to better understand all relevant costs associated with VI&B and to develop a multiperspective overview. Design: Systematic review: Two independent reviewers searched the relevant literature and assessed the studies for inclusion and exclusion criteria as well as quality. Eligibility criteria for included studies: Interventional, non-interventional and cost of illness studies, conducted prior to May 2012, investigating direct and indirect costs as well as intangible effects related to visual impairment and blindness were included. Methods: We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement approach to identify the relevant studies. A meta-analysis was not performed due to the variability of the reported cost categories and varying definition of visual impairment. Results: A total of 22 studies were included. Hospitalisation and use of medical services around diagnosis and treatment at the onset of VI&B were the largest contributor to direct medical costs. The mean annual expenses per patient were found to be US$ purchasing power parities (PPP) 12 175–14 029 for moderate visual impairment, US$ PPP 13 154–16 321 for severe visual impairment and US$ PPP 14 882–24 180 for blindness, almost twofold the costs for non-blind patients. Informal care was the major contributor to other direct costs, with the time spent by caregivers increasing from 5.8 h/week (or US$ PPP 263) for persons with vision >20/32 up to 94.1 h/week (or US$ PPP 55 062) for persons with vision ≤20/250. VI&B caused considerable indirect costs due to productivity losses, premature mortality and dead-weight losses. Conclusions: VI&B cause a considerable economic burden for affected persons, their caregivers and society at large, which increases with the degree of visual impairment. This review provides insight into the distribution of costs and the economic impact of VI&B.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The review identified 28 studies that varied in terms of disease of interest, sample size, methodology, as well as how costs were reported and valued, thus concurring with previous literature that found a high degree of heterogeneity across these types of studies [17, 21–23].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [21]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Previous literature reviews analysing costs associated with vision impairment and blindness found a high degree of heterogeneity across these studies in terms of size, methodology, as well as the way in which costs were defined and reported [17, 21–23].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
The Measurement of Observer Agreement for Categorical Data
Landis, J. R., & Koch, G. G. (1977) · Biometrics · doi:10.2307/2529310 · Cited by 81,148
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575
Methods for the Economic Evaluation of Health Care Programmes
Drummond, M. E., Sculpher, M. J., Torrance, G. W., O’Brien, B. J., & Stoddart, G. L. (2005) · doi:10.1093/oso/9780198529446.001.0001 · Cited by 13,648
Murray, C. J. L., Vos, T., Lozano, R., Naghavi, M., Flaxman, A. D., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61689-4 · Cited by 8,888
Coefficient Kappa: Some Uses, Misuses, and Alternatives
Brennan, R. L., & Prediger, D. J. (1981) · Educational and Psychological Measurement · doi:10.1177/001316448104100307 · Cited by 1,570
A cost-of-illness study of back pain in The Netherlands
van Tulder, M. W., Koes, B. W., & Bouter, L. M. (1995) · Pain · doi:10.1016/0304-3959(94)00272-g · Cited by 757
The Economic Burden of Major Adult Visual Disorders in the United States
Rein, D. B. (2006) · Archives of Ophthalmology · doi:10.1001/archopht.124.12.1754 · Cited by 635
Cited by
Public Attitudes About Eye and Vision Health
Scott, A. W., Bressler, N. M., Ffolkes, S., Wittenborn, J. S., & Jorkasky, J. (2016) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2016.2627 · Cited by 229
The economic impact of sight loss and blindness in the UK adult population
Pezzullo, L., Streatfeild, J., Simkiss, P., & Shickle, D. (2018) · BMC Health Services Research · doi:10.1186/s12913-018-2836-0 · Cited by 205
“Furthermore, no recent studies have been identified that attempt to classify absenteeism impacts [6].”
Estimating the global costs of hearing loss
McDaid, D., Park, A.-L., & Chadha, S. (2021) · International Journal of Audiology · doi:10.1080/14992027.2021.1883197 · Cited by 198
“We used prevalence-based costing, an approach that is widely used in estimating the costs of chronic conditions in different country settings (Ament and Evers 1993; Gordois et al. 2012; Koberlein et al. 2013).”
Cohort profile: design and methods in the eye and vision consortium of UK Biobank
Chua, S. Y. L., Thomas, D., Allen, N., Lotery, A., Desai, P., Patel, P., Muthy, Z., Sudlow, C., Peto, T., Khaw, P. T., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-025077 · Cited by 166
3D Printed Tablets (Printlets) with Braille and Moon Patterns for Visually Impaired Patients
Awad, A., Yao, A., Trenfield, S. J., Goyanes, A., Gaisford, S., & Basit, A. W. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020172 · Cited by 161
“In addition to issues of low medication adherence, other costs of visual impairment extend to include intangible effects such as loss of independence, depression, emotional stress, limitation in daily life activities, and excess morbidity [33], all of which can lead to a poor quality of life, especially for the elderl…”
Metadata
- Authors
- Köberlein, J., Beifus, K., Schaffert, C., & Finger, R. P.
- Affiliations
- University of Wuppertal (DE)
- University of Bonn (DE)
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2013-11
- Volume
- 3
- Issue
- 11
- Pages
- e003471
- ISSN
- 2044-6055 (ISSN-L)
- PMC
- PMC3822298
- OpenAlex
- W2170587486
- Cited by
- 226
- References
- 48
- Citations by year
- 2026: 13 · 2025: 23 · 2024: 14 · 2023: 22 · 2022: 25 · 2021: 26 · 2020: 30 · 2019: 26 · 2018: 16 · 2017: 11 · 2016: 11 · 2015: 6 · 2014: 3
- FWCI
- 0.79
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- BMJ Open (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc)
- Funders
- Deutsche Forschungsgemeinschaft
- State Government of Victoria
- Novartis Pharma
- Medical Research Council
- National Health and Medical Research Council (529923)
- Topics
- Health Sciences › Medicine › Ophthalmology › Ophthalmology and Visual Impairment Studies
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
- Keywords
- visual impairment, blindness, economic burden, direct medical costs, informal care, caregiver costs, productivity loss, premature mortality, population aging
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The economic burden of visual impairment and blindness: a systematic review. https://app.cochat.ai/papers/10.1136/bmjopen-2013-003471
- The paper
- Köberlein, J., Beifus, K., Schaffert, C., & Finger, R. P. (2013). The economic burden of visual impairment and blindness: a systematic review. BMJ Open. https://doi.org/10.1136/bmjopen-2013-003471
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.


